Literature DB >> 9226473

Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice.

C A Mora1, C A Baumann, J E Paino, A L Goldstein, M Badamchian.   

Abstract

Thymosin beta 4 (T beta 4) is a peptide of 43 amino acids that was first isolated from the thymus gland and subsequently found to be ubiquitous in nature. T beta 4 functions mainly as an actin-sequestering molecule in nonmuscle cells, where its primary role is to maintain the large pool of unpolymerized G-actin in the cell. Studies on the pharmacokinetics of T beta 4 in human and other mammals have not been reported so far. In the present study, we have measured T beta 4 concentrations in serum, urine, and 10 major organs of female Swiss-Webster mice following intraperitoneal administration of 400 micrograms synthetic T beta 4. Using a modified enzymatic immunoassay, our data show a significant increase of T beta 4 in serum starting 2 min after injection and lasting for 40 min (average: 2.34 +/- 0.54 micrograms/ml). High concentrations were found in urine (59.3 +/- 7.54 micrograms/ml) at three different points after injection (20 min, 40 min, and 2 h). Of the 400 micrograms T beta 4 administered to mice 83% was recovered at the end of the study, 44.6% of which corresponded to urine, 1.4% to serum, and 37.5% to the organs. In 50% of the tested organs, the wet weight concentrations of T beta 4 increased significantly from the first 40 min to 2 h after injection in comparison to their baseline wet weight concentrations. These organs were: the brain (72 micrograms/g), heart (80 micrograms/g), liver (15 micrograms/g vs 9 micrograms/g), kidneys (65 micrograms/g vs 28 micrograms/g), and peritoneal fat (47 micrograms/g vs 13 micrograms/g). Wet weight concentrations increased in the thymus (196 micrograms/g vs 147 micrograms/g) and muscle (45 micrograms/g vs 0 micrograms/g) after 6 h of injection. The spleen showed an increase in wet weight concentrations at the 2 min timepoint (267 micrograms/g vs 161 micrograms/g). Ovaries had a biphasic increase at 40 min (72 micrograms/g vs 62 micrograms/g) and 24 h (92 micrograms/g vs 62 micrograms/g) after T beta 4 administration. In lungs, the highest wet weight increase after injection (149 micrograms/g at timepoint 6 h) was not higher than its basal wet weight concentration (153 micrograms/g). These pharmacokinetic studies of T beta 4 in mice have established that high levels of T beta 4 are found in blood following I.P. administration and the kidney rapidly removes the peptide from the circulation. The kinetics of this response should help define the proper scheduling of administration of T beta 4 during clinical trials in disorders, such as the acute respiratory distress syndrome (ARDS), associated with actin toxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226473     DOI: 10.1016/s0192-0561(97)00005-2

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  19 in total

1.  Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke.

Authors:  D C Morris; M Chopp; L Zhang; M Lu; Z G Zhang
Journal:  Neuroscience       Date:  2010-08-25       Impact factor: 3.590

Review 2.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

3.  Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.

Authors:  Cesar A Romero; Nitin Kumar; Pablo Nakagawa; Morel E Worou; Tang-Dong Liao; Edward L Peterson; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2018-11-07

4.  Treatment of traumatic brain injury with thymosin β₄ in rats.

Authors:  Ye Xiong; Asim Mahmood; Yuling Meng; Yanlu Zhang; Zheng Gang Zhang; Daniel C Morris; Michael Chopp
Journal:  J Neurosurg       Date:  2010-05-21       Impact factor: 5.115

Review 5.  Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

Authors:  Kamal M Kassem; Sonal Vaid; Hongmei Peng; Sarah Sarkar; Nour-Eddine Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  2019-03-09       Impact factor: 2.273

6.  Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse.

Authors:  Christopher F Spurney; Hee-Jae Cha; Arpana Sali; Gouri S Pandey; Emidio Pistilli; Alfredo D Guerron; Heather Gordish-Dressman; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

7.  Thymosin β 4 mediates oligodendrocyte differentiation by upregulating p38 MAPK.

Authors:  Manoranjan Santra; Michael Chopp; Zheng Gang Zhang; Mei Lu; Sutapa Santra; Ankita Nalani; Soumi Santra; Daniel C Morris
Journal:  Glia       Date:  2012-08-01       Impact factor: 7.452

8.  Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo.

Authors:  Ildiko Bock-Marquette; Santwana Shrivastava; G C Teg Pipes; Jeffrey E Thatcher; Allissa Blystone; John M Shelton; Cristi L Galindo; Bela Melegh; Deepak Srivastava; Eric N Olson; J Michael DiMaio
Journal:  J Mol Cell Cardiol       Date:  2009-05       Impact factor: 5.000

9.  Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice.

Authors:  Lei Wang; Michael Chopp; Alexandra Szalad; Zhongwu Liu; Mei Lu; Li Zhang; Jing Zhang; Rui Lan Zhang; Dan Morris; Zheng Gang Zhang
Journal:  Neurobiol Dis       Date:  2012-08-10       Impact factor: 5.996

10.  Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction.

Authors:  Hongmei Peng; Jiang Xu; Xiao-Ping Yang; Xiangguo Dai; Edward L Peterson; Oscar A Carretero; Nour-Eddine Rhaleb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.